All In Biotech

Drug Trial Radar · NCT04901936

A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

An Open Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria

Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Feb 4, 2021

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Apellis Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, effectiveness, and biological activity (how the investigational medication is processed by the body) of pegcetacoplan in 12-17 year-olds (adolescents) who have paroxysmal nocturnal hemoglobinuria (PNH).

Conditions

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Paroxysmal Hemoglobinuria

Interventions

  • PegcetacoplanDrug

    Complement (C3) inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pegcetacoplan serum concentrations over the course of the 16-week treatment periodTime frame: 16 weeks
  2. Change from baseline to Wk 16 in hemoglobin (Hb)Time frame: 16 weeks
  3. Incidence and severity of treatment-emergent adverse events (TEAEs) over the course of the 16-week treatment period, including monitoring bacterial infectionsTime frame: 16 weeks
  4. Change from baseline to wk 16 lactate dehydrogenase (LDH)Time frame: 16 weeks
  5. Change from baseline to wk 16 absolute reticulocyte count (ARC)Time frame: 16 weeks

Locations

12 sites in 9 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Atlanta

    Atlanta, Georgia · Recruiting

  • Motol University Hospital

    Prague, Czechia · Completed

  • Robert-Debré Hospital Paris

    Paris, France · Not yet recruiting

  • Hospital Ampang

    Ampang, Malaysia · Recruiting

  • Radboud University Hospital Nijmegen

    Nijmegen, Netherlands · Completed

  • University Medical Center Utrecht

    Utrecht, Netherlands · Recruiting

  • University Children's Hospital

    Belgrade, Serbia · Recruiting

  • University Hospital Vall d'Hebron

    Barcelona, Spain · Recruiting

  • University Hospital 12 de Octubre

    Madrid, Spain · Recruiting

  • Phramongkutklao Hospital and College of Medicine

    Bangkok, Thailand · Completed

  • Maharaj Nakorn Chiang Mai hospital

    Chiang Mai, Thailand · Recruiting

  • St. Mary's Hospital

    London, United Kingdom · Completed

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.